drugset / Trial / NCT05344924
TACE Combined With Penpulimab and Anlotinib for Advanced HCC
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the optimum interval of the combination of penpulimab and anlotinib with TACE in advanced HCC patients.
Timeline
- Start
- 2022-10-12
- Primary completion
- 2023-03-31
- Completion
- 2024-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |